EXTON, Pa.--(BUSINESS WIRE)--Feb. 22, 2006--Antares Pharma, Inc. (AMEX:AIS) today announced positive results in a Phase II clinical study for Anturol(TM), the Company’s gel-based transdermal treatment for overactive bladder (OAB), a common urological condition. Anturol is a clear, odorless, and cosmetically appealing gel formulation of oxybutynin designed for optimized absorption through the skin following once-a-day application on the abdomen, shoulders, or thighs. Anturol, which utilizes Antares’ proprietary Advanced Transdermal Delivery (ATD(TM)) gel platform, is expected to begin pivotal Phase III clinical trials during the second half of 2006. Oxybutynin is considered the gold standard for OAB treatment, and is currently available only in oral dose and adhesive patch formulations.
